Neuronal Regulation of Bone Remodeling

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Seventh Edition

Volumn , Issue , 2009, Pages 56-60

  Karsenty, Gerard ^a   Elefteriou, Florent ^b  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

2 adrenergic receptor; Bone remodeling; Leptin; Neuromedin U; Neuropeptide Y; Sympathetic nervous system

Indexed keywords

EID: 77956379704     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470623992.ch10     Document Type: Chapter

References (50)

1. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil T, Shen J, Vinson C, Rueger JM, Karsenty G 2000 Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100:197-207.
2. Zigman JM, Elmquist JK 2003 Minireview: From anorexia to obe-sity-the yin and yang of body weight control. Endocrinology 144:3749-3756.
3. Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O'Rahilly S 1998 A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 20:111-112.
4. Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N, Kim CA, Ogawa Y. Liu X, Ware SM, Craigen WJ, Robert JJ, Vinson C, Nakao K, Capeau J, Karsenty G 2004 Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA 101:3258-3263.
5. Guidobono F, Pagani F, Sibilia V, Netti C, Lattuada N, Rapetti D, Mrak E, Villa I, Cavani F, Bertoni L, Palumbo C, Ferretti M, Marotti G, Rubinacci A 2006 Different skeletal regional response to continuous brain infusion of leptin in the rat. Peptides 27:1426-1433.
6. Pogoda P, Egermann M, Schnell JC, Priemel M, Schilling AF, Alini M, Schinke T, Rueger JM, Schneider E, Clarke I, Amling M 2006 Leptin inhibits bone formation not only in rodents, but also in sheep. J Bone Miner Res 21:1591-1599.
7. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G 2002 Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317.
8. Perkins MN, Rothwell NJ, Stock MJ, Stone TW 1981 Activation of brown adipose tissue thermogenesis by the ventromedial hypothalamus. Nature 289:401-102.
9. Satoh N, Ogawa Y, Katsuura G, Numata Y, Tsuji T, Hayase M, Ebihara K, Masuzaki H, Hosoda K, Yoshimasa Y, Nakao K 1999 Sympathetic activation of leptin via the ventromedial hypothalamus: Leptin-induced increase in catecholamine secretion. Diabetes 48:1787-1793.
10. Elefteriou F 2005 Neuronal signaling and the regulation of bone remodeling. Cell Mol Life Sci 62:2339-2349.
11. Denes A, Boldogkoi Z, Uhereczky G, Hornyak A, Rusvai M, Palkovits M, Kovacs KJ 2005 Central autonomic control of the bone marrow: Multisynaptic tract tracing by recombinant pseudo-rabies virus. Neuroscience 134:947-963.
12. Bonnet N, Brunet-Imbault B, Arlettaz A, Horcajada MN, Col-lomp K, Benhamou CL, Courteix D 2005 Alteration of trabecular bone under chronic beta2 agonists treatment. Med Sci Sports Ex-erc 37:1493-1501.
13. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G 2005 Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514-520.
14. Yan L, Vatner DE, O'Connor JP, Ivessa A, Ge H, Chen W, Hi-rotani S, Ishikawa Y, Sadoshima J, Vatner SF 2007 Type 5 ade-nylyl cyclase disruption increases longevity and protects against stress. Cell 130:247-258.
15. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G 2005 The molecular clock mediates leptin-regulated bone formation. Cell 122:803-815.
16. Simmons DJ, Nichols G Jr 1966 Diurnal periodicity in the metabolic activity of bone tissue. Am J Physiol 210:411-418.
17. Gundberg CM, Markowitz ME, Mizruchi M, Rosen JF 1985 Osteocalcin in human serum: A circadian rhythm. J Clin Endocrinol Metab 60:736-739.
18. Arai M, Nagasawa T, Koshihara Y, Yamamoto S, Togari A 2003 Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim Biophys Acta 1640:137-142.
19. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, Li L. Brancorsini S, Sassone-Corsi P, Townes TM, Hanauer A, Karsenty G 2004 ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 117:387-398.
20. Lorentzon M, Landin K, Mellstrom D, Ohlsson C 2006 Leptin is a negative independent predictor of areal BMD and cortical bone size in young adult Swedish men. J Bone Miner Res 21:1871-1878.
21. Pasco J, Henry M, Sanders K, Kotowicz M, Seeman E, Nicholson G 2003 Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. J Bone Miner Res 19:19-24.
22. Schlienger RG, Kraenzlin ME. Jick SS, Meier CR 2004 Use of beta-blockers and risk of fractures. JAMA 292:1326-1332.
23. Rejnmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brixen K, Mosekilde L 2004 Fracture risk in peri-menopausal women treated with beta-blockers. Calcif Tissue Int 75:365-372.
24. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC 2004 Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 19:19-24.
25. Wiens M, Etminan M, Gill SS, Takkouche B 2006 Effects of antihypertensive drug treatments on fracture outcomes: A metaanalysis of observational studies. J Intern Med 260:350-362.
26. Rejnmark L, Vestergaard P, Mosekilde L 2006 Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: A nationwide case-control study. J Hypertens 24:581-589.
27. Reid IR. Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC 2005 beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20:613-618.
28. Levasseur R, Marcelli C, Sabatier JP, Dargent-Molina P, Breart G 2005 Beta-blocker use, bone mineral density, and fracture risk in older women: Results from the Epidemiologie de l'Osteoporose prospective study. J Am Geriatr Soc 53:550-552.
29. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, Clausen JT, Jensen PB, Madsen OD, Vrang N, Larsen PJ, Hastrup S 1998 Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393:72-76.
30. Ahn JD, Dubern B, Lubrano-Berthelier C, Clement K, Karsenty G 2006 Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology 147:3196-3202.
31. Orwoll B, Bouxsein ML, Marks DL, Cone RD, Klein RF 2004 Increased bone mass and strength in melanocortin-4 receptor-deficient mice ORS/AAOS Presentations 2003,71st Annual Meeting of the AAOS, San Francisco, CA, USA, March 2003.
32. Brighton PJ, Szekeres PG, Willars GB 2004 Neuromedin U and its receptors: Structure, function, and physiological roles. Pharmacol Rev 56:231-248.
33. Hanada R, Teranishi H, Pearson JT, Kurokawa M, Hosoda H, Fukushima N, Fukue Y, Serino R, Fujihara H, Ueta Y, Ikawa M, Okabe M, Murakami N, Shirai M, Yoshimatsu H, Kangawa K, Kojima M 2004 Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway. Nat Med 10:1067-1073.
34. Sato S, Hanada R, Kimura A, Abe T, Matsumoto T, Iwasaki M, Inose H, Ida T, Mieda M, Takeuchi Y, Fukumoto S, Fujita T, Kato S, Kangawa K, Kojima M, Shinomiya KI, Takeda S 2007 Central control of bone remodeling by neuromedin U. Nat Med 13:1234-1240.
35. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog H 2002 Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109:915-921.
36. Sainsbury A, Baldock PA, Schwarzer C, Ueno N, Enriquez RF, Couzens M, Inui A, Herzog H, Gardiner EM 2003 Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol Cell Biol 23:5225-5233.
37. Baldock PA, Allison S, Sainsbury A, Enriquez RF, Gardiner EM, Herzog H, Eisman JA 2006 Hypothalamic neuropeptide Y exerts a negative effect on cortical bone formation. 28th Annual Meeting of the American Society for Bone and Mineral Research, September 2006, Philadelphia. PA, USA.
38. Elefteriou F, Takeda S, Liu X, Armstrong D, Karsenty G 2003 Monosodium glutamate-sensitive hypothalamic neurons contribute to the control of bone mass. Endocrinology 144:3842-3847.
39. van't Hof RJ, Macphee J, Libouban H, Helfrich MH, Ralston SH 2004 Regulation of bone mass and bone turnover by neuronal nitric oxide synthase. Endocrinology 145:5068-5074.
40. Lutz B 2002 Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 66:123-142.
41. Idris AI, van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH 2005 Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11:774-779.
42. Tarn J, Ofek O, Fride E, Ledent C, Gäbet Y, Muller R, Zimmer A, Mackie K, Mechoulam R, Shohami E, Bab I 2006 Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 70:786-792.
43. Tarn J, Alexandrovich A, Di Marzo V, Petrosino S, Trembovler V, Zimmer A, Ledent C, Mackie K, Mechoulam R, Shohami E, Bab I 2006 CB1, but not CB2 cannabinoid receptor mediates stimulation of bone formation induced by traumatic brain injury. 28th Annual Meeting of the American Society for Bone and Mineral Research, September 2006, Philadelphia, PA, USA.
44. Devoto M, Shimoya K, Caminis J, Ott J, Tenenhouse A, Whyte MP, Sereda L, Hall S, Considine E, Williams CJ, Tromp G, Kui-vaniemi H, Ala-Kokko L, Prockop DJ, Spotila LD 1998 First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes lp, 2p and 4q. Eur J Hum Genet 6:151-157.
45. van't Hof RJ, Ralston SH 2001 Nitric oxide and bone. Immunology 103:255-261.
46. Helfrich MH, Evans DE, Grabowski PS, Pollock JS, Ohshima H. Ralston SH 1997 Expression of nitric oxide synthase isoforms in bone and bone cell cultures. J Bone Miner Res 12:1108-1115.
47. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G 1996 Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118:2023-2028.
48. Ballica R, Valentijn K, Khachatryan A, Guerder S, Kapadia S, Gundberg C, Gilligan J, Flavell RA, Vignery A 1999 Targeted expression of calcitonin gene-related peptide to osteoblasts increases bone density in mice. J Bone Miner Res 14:1067-1074.
49. Schinke T, Liese S, Prieme! M, Haberland M, Schilling AF, Catala-Lehnen P. Blicharski D, Rueger JM, Gagel RF, Emeson RB, Amling M 2004 Decreased bone formation and osteopenia in mice lacking alpha-calcitonin gene-related peptide. J Bone Miner Res 19:2049-2056.
50. Amano S, Arai M, Goto S, Togari A 2007 Inhibitory effect of NPY on isoprenaline-induced osteoclastogenesis in mouse bone marrow cells. Biochim Biophys Acta 1770:966-973.